Cochrane · systematic review · CD003256
Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults
Gbabe, OF, Okwundu, CI, Dedicoat, M, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
29
current version
GRADE rated
29
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 20.7%Low 0 · 0%Moderate 23 · 79.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality HAART + ABV vs HAART alone | RR 0.92 [0.45, 1.88] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Progressive disease HAART + ABV vs HAART alone | RR 0.1 [0.01, 0.75] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Clinical response ‐ complete response HAART + ABV vs HAART alone | RR 2 [0.64, 6.22] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Clinical response ‐ partial response HAART + ABV vs HAART alone | RR 1.71 [1.01, 2.91] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Clinical response ‐ stable disease HAART + ABV vs HAART alone | RR 0.06 [0, 0.99] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Clinical response ‐ overall response (complete and partial) HAART + ABV vs HAART alone | RR 1.78 [1.16, 2.72] | 1 study · 100 participants | Moderate Downgraded: imprecision |
Adverse events HAART + ABV vs HAART alone | RR 0.88 [0.59, 1.32] | 1 study · 100 participants | Moderate Downgraded: imprecision |
HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical response HAART + pegylated liposomal doxorubicin vs HAART alone | RR 9 [0.61, 133.08] | 1 study · 10 participants | Moderate Downgraded: imprecision |
HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality HAART + liposomal anthracycline vs HAART alone | RR 1.23 [0.35, 4.38] | 1 study · 129 participants | Moderate Downgraded: imprecision |
Kaposi's sarcoma IRIS HAART + liposomal anthracycline vs HAART alone | RR 0.49 [0.16, 1.55] | 1 study · 129 participants | Moderate Downgraded: imprecision |
HAART + paclitaxel compared to HAART + pegylated liposomal doxorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of Kaposi's sarcoma HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin | RR 1.04 [0.07, 15.73] | 1 study · 49 participants | Moderate Downgraded: imprecision |
Clinical response ‐ complete response HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin | RR 2.08 [0.2, 21.5] | 1 study · 49 participants | Moderate Downgraded: imprecision |
Clinical response ‐ partial response HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin | RR 1.04 [0.5, 2.17] | 1 study · 49 participants | Moderate Downgraded: imprecision |
Clinical response ‐ stable disease HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin | RR 0.63 [0.27, 1.45] | 1 study · 49 participants | Moderate Downgraded: imprecision |
HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of Kaposi's sarcoma HAART + pegylated liposomal doxorubicin vs HAART + liposomal daunorubicin | no estimate extracted | 1 study · 46 participants | Moderate Downgraded: imprecision |
Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of Kaposi's sarcoma Liposomal daunorubicin vs ABV | RR 0.78 [0.34, 1.82] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Clinical response ‐ complete response Liposomal daunorubicin vs ABV | RR 2.87 [0.3, 27.19] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Clinical response ‐ partial response Liposomal daunorubicin vs ABV | RR 0.83 [0.53, 1.31] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Clinical response ‐ overall response Liposomal daunorubicin vs ABV | RR 0.9 [0.58, 1.38] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Clinical response ‐ stable disease Liposomal daunorubicin vs ABV | RR 1.08 [0.87, 1.33] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Adverse events Liposomal daunorubicin vs ABV | RR 1.01 [0.96, 1.06] | 1 study · 227 participants | Moderate Downgraded: imprecision |
Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Oral etoposide vs ABV | RR 1.08 [0.98, 1.19] | 1 study · 178 participants | Moderate Downgraded: imprecision |
Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Bleomycin vs ABV | RR 1.09 [0.87, 1.36] | 1 study · 24 participants | Very low Downgraded: imprecision |
Clinical response ‐ complete response Bleomycin vs ABV | no estimate extracted | 1 study · 24 participants | Very low Downgraded: imprecision |
Clinical response ‐ partial response Bleomycin vs ABV | RR 0.11 [0.01, 1.86] | 1 study · 24 participants | Very low Downgraded: imprecision |
Clinical response ‐ stable disease Bleomycin vs ABV | RR 0.88 [0.47, 1.63] | 1 study · 24 participants | Very low Downgraded: imprecision |
Clinical response ‐ progression Bleomycin vs ABV | RR 11 [0.67, 179.29] | 1 study · 24 participants | Very low Downgraded: imprecision |
Adverse events Bleomycin vs ABV | RR 11 [0.67, 179.29] | 1 study · 24 participants | Very low Downgraded: imprecision |
Liposomal doxorubicin compared to conservative management for the treatment of severe Kaposi's sarcoma in HIV‐infected adults
Population: HIV‐infected adults with severe (T1) Kaposi's sarcoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Liposomal doxorubicin vs conservative management | RR 0.93 [0.75, 1.15] | 1 study · 29 participants | Moderate Downgraded: imprecision |